Identification of a Pure Splenic Form of Chronic Lymphocytic Leukaemia

Dighiero, Guillaume; Charron, Dominique; Debré, Patrice; Porrier, M. Le; Vaugier, G; Follezou, J. Y.; Degos, Laurent; Jacquillat, C; Binet, Jacques‐Louis

doi:10.1111/j.1365-2141.1979.tb05845.x

Cited by 38 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,21 Also the studies on surface Ig support the importance of the evaluation of the size of organomegalies. A prevalence of surface IgMK has in fact been observed in the older patients and in females, with or without minimal organomegalies.…”

Section: Lmentioning

confidence: 96%

Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases

Paolino

Infelise

Levis

et al. 1984

Cancer

View full text Add to dashboard Cite

Presence and size of lymph nodes and spleen, graded from 0 to +++, in 362 patients with CLL observed from diagnosis were evaluated. Statistical analysis showed a relationship with age, sex, anemia and thrombopenia, leukocytosis, and outlined two different groups: the one without organomegalies, with higher mean age (67 years), female prevalence, and better prognosis; the other with adenosplenomegaly graded ++/+++, with lower mean age (57 years), clear male prevalence, and worse prognosis. Survival results were statistically different only between groups 0/+ versus group ++/+++. Important chronic diseases were present at diagnosis in approximately 25% of the cases, with a severely reduced survival (median, 27 months), close to that of the cases with anemia and/or thrombopenia (22 months). Therefore it seems that in every prognostic grouping system, complicated cases should be taken into account and grouped with the anemic and/or the thrombopenic ones. The following prognostic groups are proposed: I: low risk: cases without or with adenomegaly and/or splenomegaly + (65% surviving at 100 months); II: intermediate risk: cases with adenomegaly and/or splenomegaly ++/+++ (median survival, 70 months); III: high risk: cases complicated by chronic diseases, or with anemia and/or thrombopenia (median survival, 25 months).

show abstract

Section: Lmentioning

confidence: 96%

Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases

Paolino

Infelise

Levis

et al. 1984

Cancer

View full text Add to dashboard Cite

show abstract

“…Lymphadenopathy is usually more prominent than splenomegaly, but 4-6°/o of the patients present with modest splenomegaly without lymphadenopathy [13]. CLL is not associated with leukopenia.…”

Section: Resultsmentioning

confidence: 99%

Clinical Differential Diagnosis of Hairy-Cell Leukaemia

Jansen¹,

Ottolander²,

Velde³

et al. 1980

Acta Haematol

View full text Add to dashboard Cite

The data on hairy-cell leukaemia (HCL) and resembling disorders in the literature and in our patients were analyzed to determine which clinical features and laboratory data are important for the recognition of HCL in an early stage. In pancytopenic patients the typical pattern of bone marrow involvement in HCL and the low number of monocytes in the peripheral blood appear to be essential for the differential diagnosis. In patients with many neoplastic cells in the peripheral blood, the presence of neutropenia and monocytopenia as well as tartrate-resistant acid phosphatase activity in the neoplastic cells, appears to be crucial for early diagnosis. Thus, the clinical features and routine laboratory data alone are sufficient in the majority of cases to suggest the diagnosis HCL. The monocytopenia proved to be most helpful in this respect. Nevertheless, in all patients, and certainly in patients presenting with atypical features, a bone marrow biopsy is indispensable for the correct diagnosis.

show abstract

“…Third, the cytoskeleton is a major target of the events which transform cells and lead to malignancy (reviewed in [23]). We have chosen B-CLL cells as model since these cells have several abnormalities indicating unusual features in the organization and function of their cytoskeleton [6][7][8][9][24][25][26][27].…”

Section: Discussionmentioning

confidence: 99%

CDS and CD21 molecules are a functional unit in the cell/substrate adhesion of B‐chronic lymphocytic leukemia cells

et al. 1988

View full text Add to dashboard Cite

The modulation of surface molecules on B-chronic lymphocytic leukemia (B-CLL) cells was studied in vitro by incubation with CD19, CD20, CD21, CD5 and anti-IgM antibodies. The cytoplasmic changes were evaluated by analyzing the organization of cytoskeletal F-actin and the adhesive properties of stimulated B-CLL cells. The following observations were made: (a) CD5 antigen is capped on the surface of B-CLL cells (but not on normal CD5+ B and T lymphocytes). (b) On B-CLL cells, CD5 and CD21, the receptors for the C3d fraction of complement, co-cap and co-modulate while surface IgM as well as CD19 and CD20 do not cap. (c) B-CLL cells, after capping of CD5 or CD21 surface molecules, fail to organize F-actin into podosomes. (d) The pre-incubation of B-CLL cells with either CD5 or CD21 antibodies prevents their binding to purified C3d protein used to coat coverslips. These data indicate that an intimate spatial relationship exists between CD5 and CD21 molecules on the B-CLL surface. The CD5-CD21 complex is involved in the redistribution of cytoskeletal proteins which may control the adhesive properties of these malignant B cells.

show abstract

Identification of a Pure Splenic Form of Chronic Lymphocytic Leukaemia

Cited by 38 publications

References 13 publications

Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases

Adenosplenomegaly and prognosis in uncomplicated and complicated chronic lymphocytic leukemia. A study of 362 cases

Clinical Differential Diagnosis of Hairy-Cell Leukaemia

CDS and CD21 molecules are a functional unit in the cell/substrate adhesion of B‐chronic lymphocytic leukemia cells

Contact Info

Product

Resources

About